Palogic Value Management L.P. bought a new stake in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 320,000 shares of the company's stock, valued at approximately $2,262,000. Palogic Value Management L.P. owned about 0.53% of Health Catalyst at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in Health Catalyst in the fourth quarter valued at approximately $29,000. Quest Partners LLC purchased a new position in shares of Health Catalyst during the 3rd quarter valued at $34,000. Stoneridge Investment Partners LLC purchased a new position in shares of Health Catalyst during the 4th quarter valued at $77,000. Quadrature Capital Ltd bought a new position in shares of Health Catalyst during the 3rd quarter worth $84,000. Finally, Virtu Financial LLC purchased a new stake in Health Catalyst in the 4th quarter worth about $110,000. 85.00% of the stock is currently owned by institutional investors.
Insider Activity at Health Catalyst
In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the sale, the chief operating officer now directly owns 91,253 shares in the company, valued at $685,310.03. The trade was a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares of the company's stock, valued at approximately $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 56,530 shares of company stock worth $299,572 over the last 90 days. 2.50% of the stock is owned by company insiders.
Health Catalyst Trading Up 2.8 %
Shares of NASDAQ:HCAT traded up $0.12 during midday trading on Wednesday, hitting $4.45. 165,631 shares of the stock traded hands, compared to its average volume of 614,137. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business's 50 day moving average is $4.98 and its two-hundred day moving average is $6.80. The stock has a market capitalization of $312.44 million, a PE ratio of -3.30 and a beta of 1.41. Health Catalyst, Inc. has a one year low of $3.76 and a one year high of $9.24.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on HCAT shares. Royal Bank of Canada decreased their price objective on Health Catalyst from $7.00 to $6.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 27th. Piper Sandler cut their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 11th. Stephens decreased their target price on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, March 6th. Citigroup dropped their price objective on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Finally, Stifel Nicolaus cut their price objective on Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Health Catalyst currently has a consensus rating of "Moderate Buy" and a consensus price target of $9.27.
Check Out Our Latest Research Report on HCAT
About Health Catalyst
(
Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Further Reading
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
